Why Quotes Go Wrong: What Sponsors Often Miss When Engaging Synthesis Partners

Why Quotes Go Wrong: What Sponsors Often Miss When Engaging Synthesis Partners

What to Send a Synthesis Partner to Get a Fast, Accurate Quote (and Avoid Scope Drift)

One of the fastest ways to lose time in a chemistry program is an avoidable loop of clarification emails:

  • “What purity do you need?”
  • “Do you have a preferred salt form?”
  • “Is this for discovery or cGMP?”
  • “Do you need plate formatting?”
  • “Do you require method development or just release testing?”

You can compress that cycle dramatically by sending a complete, sponsor-friendly request package upfront. Here’s a practical checklist that works across research compounds, APIs, and CDMO engagements.

1) Compound identity and structure package

Include:
  • structure file (SMILES/MOL/SDF preferred)
  • CAS (if available)
  • internal compound ID(s)
  • stereochemistry notes (if relevant)
  • known stability concerns (light, moisture, oxidation)

Why it matters: feasibility, route choice, analytical approach, and risk profile all start here.

2) Quantity and delivery format

Include:
  • target quantity (and whether it’s a one-time need or recurring)
  • preferred delivery format:
    • single vial vs multi-vial set
    • plate-ready format for libraries
    • free base vs salt
  • concentration or solvent requirements (if applicable)

Why it matters: packaging, QC sampling, and production planning change based on format.

3) Specifications and acceptance criteria

Include:
  • purity target (and method preference if you have one)
  • assay target and tolerances
  • critical impurity constraints (if known)
  • residual solvent limits (if you have a standard)
  • any elemental impurity constraints (stage-dependent)

Why it matters: “high purity” is not a single standard. Target criteria drive route and purification decisions.

4) Program stage and required grade

Include:
  • discovery / screening
  • lead optimization
  • preclinical / tox
  • clinical (non-GMP vs cGMP)
  • commercial readiness considerations (if relevant)

Why it matters: documentation, QA oversight, testing expectations, and release processes vary by stage.

5) Analytical expectations and documentation

Include what you expect to receive:
  • CoA detail level
  • identity confirmation expectations
  • raw data needs (if any)
  • method development/optimization needs
  • stability planning/studies (if in scope)
  • CMC/regulatory support needs (if applicable)

Why it matters: misalignment here causes the most common scope changes.

6) Timeline, shipping, and handling constraints

Include:
  • required delivery date (and whether timing is “hard” or “preferred”)
  • destination country
  • cold-chain needs (if any)
  • storage requirements
  • hazardous/potency handling notes (if relevant)

Why it matters: logistics can be as schedule-critical as synthesis.

7) For analogue series and libraries: add a mapping table

If you need multiple compounds:

  • list each target with structure/ID
  • specify common core + variable positions
  • note desired plate map or vial labeling scheme
  • define “must-have” vs “nice-to-have” compounds if time is tight

Why it matters: avoids confusion, accelerates execution, and prevents labeling errors.